Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.18 -1.7%	$1.30	$0.86 ▼ $3.78	$258.10M	0.31	3.26 million shs	5.18 million shs
OLMA Olema Pharmaceuticals	$4.62 +1.3%	$4.69	$2.86 ▼ $16.62	$316.10M	2	824,299 shs	3.46 million shs
ORMP Oramed Pharmaceuticals	$2.15 -0.9%	$2.22	$1.82 ▼ $3.09	$87.83M	1.63	142,318 shs	59,111 shs
TRDA Entrada Therapeutics	$6.91 -1.6%	$8.03	$6.80 ▼ $21.79	$262.23M	-0.06	133,521 shs	545,179 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-4.07%	+1.29%	-19.18%	-49.36%
OLMA Olema Pharmaceuticals	0.00%	+11.86%	-13.16%	+22.87%	-57.30%
ORMP Oramed Pharmaceuticals	0.00%	+0.94%	-8.51%	+0.47%	-16.34%
TRDA Entrada Therapeutics	0.00%	-2.95%	-9.79%	-23.56%	-51.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.5173 of 5 stars	4.5	1.0	2.8	3.3	0.6
OLMA Olema Pharmaceuticals	2.6227 of 5 stars	3.5	1.0	3.3	2.5	0.6
ORMP Oramed Pharmaceuticals	0.5842 of 5 stars	0.0	3.0	1.9	0.8	0.6
TRDA Entrada Therapeutics	3.1627 of 5 stars	3.6	2.0	2.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	615.63% Upside
OLMA Olema Pharmaceuticals	3.00	Buy	$24.50	430.30% Upside
ORMP Oramed Pharmaceuticals	2.00	Hold	N/A	N/A
TRDA Entrada Therapeutics	3.25	Buy	$25.67	271.44% Upside

Current Analyst Ratings Breakdown

Latest ORMP, ALLO, OLMA, and TRDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/14/2025	OLMA Olema Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $18.00
5/14/2025	OLMA Olema Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $22.00
4/28/2025	OLMA Olema Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	12,905.07	N/A	N/A	$2.01 per share	0.59
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	$7.14 per share	N/A
ORMP Oramed Pharmaceuticals	$1.34M	65.54	N/A	N/A	$3.61 per share	0.60
TRDA Entrada Therapeutics	$210.78M	1.24	$1.59 per share	4.35	$11.46 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
OLMA Olema Pharmaceuticals	-$129.47M	-$2.01	N/A	N/A	N/A	N/A	-42.31%	-38.32%	8/5/2025 (Estimated)
ORMP Oramed Pharmaceuticals	-$19.06M	-$0.44	N/A	N/A	N/A	N/A	-11.34%	-10.73%	8/13/2025 (Estimated)
TRDA Entrada Therapeutics	$65.63M	$0.81	8.53	N/A	N/A	14.39%	5.84%	4.61%	8/12/2025 (Estimated)

Latest ORMP, ALLO, OLMA, and TRDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ORMP Oramed Pharmaceuticals	-$0.03	-$0.19	-$0.16	-$0.19	N/A	$2.00 million
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/13/2025	Q1 2025	OLMA Olema Pharmaceuticals	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
OLMA Olema Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
OLMA Olema Pharmaceuticals	N/A	15.22	15.22
ORMP Oramed Pharmaceuticals	N/A	23.94	23.94
TRDA Entrada Therapeutics	N/A	21.88	21.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
OLMA Olema Pharmaceuticals	91.78%
ORMP Oramed Pharmaceuticals	12.73%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
OLMA Olema Pharmaceuticals	16.36%
ORMP Oramed Pharmaceuticals	13.70%
TRDA Entrada Therapeutics	7.59%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
OLMA Olema Pharmaceuticals	70	68.42 million	57.23 million	Optionable
ORMP Oramed Pharmaceuticals	10	40.85 million	35.25 million	Optionable
TRDA Entrada Therapeutics	110	37.95 million	35.07 million	Optionable

ORMP, ALLO, OLMA, and TRDA Headlines

Recent News About These Companies

Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Upgraded by Wall Street Zen

June 29 at 2:07 AM | americanbankingnews.com

Entrada Therapeutics (NASDAQ:TRDA) Upgraded to "Hold" at Wall Street Zen

June 27 at 12:09 AM | marketbeat.com

Wall Street Zen Downgrades Entrada Therapeutics (NASDAQ:TRDA) to Sell

June 14, 2025 | marketbeat.com

Millennium Management LLC Sells 98,416 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

June 12, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Position Trimmed by Nuveen Asset Management LLC

June 4, 2025 | marketbeat.com

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025 | globenewswire.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...

May 29, 2025 | morningstar.comM

Entrada Therapeutics to start DMD trial in Q3 2025

May 29, 2025 | investing.com

Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025

May 29, 2025 | nasdaq.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28, 2025 | globenewswire.com

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

May 11, 2025 | finance.yahoo.com

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Entrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other Candidates

May 2, 2025 | precisionmedicineonline.comP

Entrada Cuts 20% of Workforce, Targeting Research Employees

April 30, 2025 | biospace.comB

Entrada lays off 20% of staff weeks after having FDA hold lifted

April 30, 2025 | fiercebiotech.comF

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

April 29, 2025 | zacks.com

Entrada Therapeutics Receives UK Approval To Start Phase 1/2 Trial Of ENTR-601-45 For DMD

March 26, 2025 | nasdaq.com

Entrada receives authorization in the UK to initiate ELEVATE-45-201 study

March 25, 2025 | markets.businessinsider.com

Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK

March 24, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Addition by Subtraction: Intel’s New Strategy Energizes Investors
By Jeffrey Neal Johnson | June 27, 2025
View Addition by Subtraction: Intel’s New Strategy Energizes Investors
Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
By Leo Miller | June 14, 2025
View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
HSAs for Gym Memberships? These 3 Fitness Stocks Could Soar
By Chris Markoch | June 24, 2025
View HSAs for Gym Memberships? These 3 Fitness Stocks Could Soar
Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY
By Thomas Hughes | June 11, 2025
View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY

ORMP, ALLO, OLMA, and TRDA Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.18 -0.02 (-1.67%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.18 0.00 (-0.42%)

As of 06/27/2025 07:58 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Olema Pharmaceuticals NASDAQ:OLMA

$4.62 +0.06 (+1.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.58 -0.04 (-0.95%)

As of 06/27/2025 07:05 PM Eastern

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Oramed Pharmaceuticals NASDAQ:ORMP

$2.15 -0.02 (-0.92%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.14 -0.01 (-0.42%)

As of 06/27/2025 04:06 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Entrada Therapeutics NASDAQ:TRDA

$6.91 -0.11 (-1.57%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.90 -0.02 (-0.22%)

As of 06/27/2025 04:34 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time